Evidence map›Paper›PMID 32040910›Full record

ReviewBiomacromolecules2020

Enzymatic Degradation of

Chengchen Guo, Chunmei Li, David L Kaplan

Abstract readReview
In one paragraph

Review in Biomacromolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Silk protein plastics for sustained and controlled drug release.International journal of pharmaceutics · 2026
    Article
  9. Article
  10. Recent Advances in Silk Fibroin Derived fromJournal of functional biomaterials · 2025
    Review
  11. Silk Fibroin Particle-Laden Sponges as a Multiphase Controlled Release Platform.Regenerative engineering and translational medicine · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Manipulating the Assembly and Architecture of Fibrillar Silk.Advanced materials (Deerfield Beach, Fla.) · 2025
    Article
  18. Review
  19. Review
  20. Photobonding of silk fibroin-based hydrogels to rabbit corneas.Frontiers in bioengineering and biotechnology · 2025
    Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chengchen GuoDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States.ORCID 0000-0001-9253-3469
Chunmei LiDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States.
David L KaplanDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts 02155, United States.ORCID 0000-0002-9245-7774

Funding

Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Tissue Engineering Resource Center: TTDP41EB027062 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gordana Vunjak-Novakovic · 2019 to 2026
$12.6M
Models to Predict Protein Biomaterial PerformanceU01EB014976 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI BUEHLER, MARKUS J., KAPLAN, DAVID L. · 2012 to 2020
$5.2M
Degradable orthopedic hardwareR01AR068048 · NIAMS · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L., LIN, SAMUEL J · 2015 to 2020
$2.0M
Focal Sustained Release Chemotherapy-Loaded Biomaterials at Tumor SitesR01NS094218 · NINDS · TUFTS UNIVERSITY MEDFORD · PI CHIU, BILL, KAPLAN, DAVID L. · 2017 to 2021
$1.7M
Intra-Articular Delivery of Sustained Release NF-kB Antagonists In ArthritisR01AR070975 · NIAMS · WASHINGTON UNIVERSITY · PI SETTON, LORI A. · 2017 to 2021
$1.7M
Injectable Gels for Tissue AugmentationR01EB021264 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI HOUSE, MICHAEL DOUGLAS, KAPLAN, DAVID L. · 2016 to 2019
$1.4M
NIAMS NIH HHS R01 AR068048NIAMS NIH HHS R01 AR070975NIBIB NIH HHS P41 EB002520NIBIB NIH HHS P41 EB027062NIBIB NIH HHS R01 EB021264NIBIB NIH HHS U01 EB014976NINDS NIH HHS R01 NS094218
6 · The paper itself

Abstract

As a biomaterial, silk presents unique features with a combination of excellent mechanical properties, biocompatibility, and biodegradability. The biodegradability aspects of silk biomaterials, especially with options to control the rate from short (days) to long (years) time frames in vivo, make this protein-based biopolymer a good candidate for developing biodegradable devices used for tissue repairs and tissue engineering, as well as medical device implants. Silk materials, including native silk fibers and a broad spectrum of regenerated silk materials, have been investigated in vitro and in vivo to demonstrate degradation by proteolytic enzymes. In this Review, we summarize the findings on these studies on the enzymatic degradation of

Indexed as

BombyxFibroinsAnimalsBiocompatible MaterialsSilkTissue EngineeringBiocompatible MaterialsFibroinsSilk

Identifiers

PMID32040910
PMCPMC7645160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.